NVIDIA Partners With Novo Nordisk and DCAI to Advance Drug Discovery

Core Viewpoint - NVIDIA collaborates with Novo Nordisk to enhance drug discovery through advanced AI technologies, utilizing the Gefion supercomputer for innovative research and development applications [1][3][13] Group 1: Collaboration and Technology - The partnership aims to create customized AI models for early research and clinical development, leveraging advanced simulation and physical AI technologies [2] - Gefion, powered by NVIDIA DGX SuperPOD™, serves as an AI factory for Novo Nordisk, enabling the execution of drug discovery and agentic AI workloads [3][5] - NVIDIA's tools, including BioNeMo™, NIM™, and NeMo™, will facilitate generative AI-powered drug discovery and the development of customized workflows [3] Group 2: Research Focus - Novo Nordisk researchers will utilize single-cell models to predict cellular responses to drug candidates and design models for drug-like molecules [4] - The collaboration will also focus on building biomedical large language models from Novo Nordisk's extensive scientific literature to identify correlations between genes, proteins, and diseases [4] Group 3: Impact on Healthcare - Gefion's computational power is expected to address significant R&D challenges, aiming to unlock new possibilities in pharmaceutical research and development [6] - Danish startup Teton is using Gefion to develop an AI care companion for hospitals, which has shown a 25% reduction in nightshift duties for nurses [7] - Gefion will support efforts to unify health data across Danish health organizations, facilitating secure access to interconnected health data for research [9]